Steminent Biotherapeutics (ROCO:7729) Interest Expense : NT$-1.92 Mil (TTM As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Steminent Biotherapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Steminent Biotherapeutics's interest expense for the six months ended in Dec. 2024 was NT$ -0.92 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-1.92 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Steminent Biotherapeutics's Operating Income for the six months ended in Dec. 2024 was NT$ -76.51 Mil. Steminent Biotherapeutics's Interest Expense for the six months ended in Dec. 2024 was NT$ -0.92 Mil. Steminent Biotherapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Steminent Biotherapeutics Interest Expense Historical Data

The historical data trend for Steminent Biotherapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Steminent Biotherapeutics Interest Expense Chart

Steminent Biotherapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

-0.79

-1.33

-0.90

-1.78

-1.92

Steminent Biotherapeutics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Interest Expense	Get a 7-Day Free Trial			-0.64	-0.71	-1.08	-1.00	-0.92

Steminent Biotherapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.92 Mil.

Steminent Biotherapeutics (ROCO:7729) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Steminent Biotherapeutics's Interest Expense for the six months ended in Dec. 2024 was NT$-0.92 Mil. Its Operating Income for the six months ended in Dec. 2024 was NT$-76.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2024 was NT$50.09 Mil.

Steminent Biotherapeutics's Interest Coverage for the quarter that ended in Dec. 2024 is calculated as

Steminent Biotherapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Steminent Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Steminent Biotherapeutics Inc (ROCO:7729) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.16,Wenhu Street, Neihu District, Taipei, TWN, 11445

Website

http://www.steminent.com

Steminent Biotherapeutics Inc is a international stem cell biopharmaceutical company which has stable and efficient stem cell platform technology, aiming to develop live cell drugs to treat degenerative diseases as well as acute and life-threatening diseases. With its Stemchymal which is proprietary technology platform generating the standardized, clinical grade, allogeneic stem cells isolated from human adipose tissue. It is operated in strict compliance to regulations of Taiwan, the US, and Japan.

Steminent Biotherapeutics Headlines

No Headlines